---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-24-000194"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:45:30.630156+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GoodRx Q3 2024 revenue $195.3M, net income $4.0M, Adjusted EBITDA $65.0M

## Summary
- Revenue and Adjusted Revenue both $195.3 million for Q3 2024.
- Net income of $4.0 million (2.0% margin); Adjusted Net Income $31.9 million (16.4% margin).
- Adjusted EBITDA $65.0 million (33.3% margin); operating cash flow $86.9 million.
- Exited Q3 with over 7 million consumers of prescription-related offerings.
- Expects ~20% YoY growth in pharma manufacturer solutions for Q4 2024 and 20%+ for FY 2025.

## SEC filing metadata
- accession: 0001809519-24-000194
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000194/0001809519-24-000194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000194/gdrx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-24-000194
- JSON: https://secwatch.observer/filing/0001809519-24-000194.json
- Plain text: https://secwatch.observer/filing/0001809519-24-000194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.